Investigation of Cross-Resistance between Rifampin and Rifabutin in Multi-Drug Resistant Mycobacterium tuberculosis

Liping Yan, Li Gao, Zhenling Cui, Zhongyi Hu, Junmei Lu, Xiaona Shen and Heping Xiao*
Department of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

Abstract
Objective: In order to indicate the cross-resistance between rifampin (RFP) and rifabutin (RFB) in multi-drug resistant Mycobacterium tuberculosis (MDR-TB) clinical strains and to provide the laboratory data for using rifabutin in the treatment of MDR-TB.

Methods: The minimal inhibitory concentrations (MICs) of RFB and RFP in 7H10 Middlebrook medium against 99 MDR-TB clinical strains were determined by microplate assays.

Results: Among these 99 isolates, 85 were resistant to rifabutin at concentrations >0.5 µg/ml. The cross-resistance ratio between rifampin and rifabutin was 85.86%. The MICs of rifampin were 8-32 times lower than those of rifabutin (χ²=125.905, p<0.001). The cross-resistance ratio increased with the resistance level of RFP. The cross-resistance strains in the lower (the MICs of RFB ≥ 2 µg/ml) and medium groups (the MICs of RFB 8 ~ 16 µg/ml) were 0/9 and 5/9 respectively, while in the high rifampin-resistant group (the MICs of RFB ≥ 32 µg/ml) almost all of the strains but one were cross-resistant (98.8%, 80/81).

Conclusion: RFB has the activities against MDR-TB clinical strains in vitro. The cross-resistance ratio between rifampin and rifabutin increased with the resistance level of RFP. RFB is one of alternatives for the treatment of MDR-TB.

Keywords: Rifabutin; Rifampin; Mycobacterium tuberculosis; Multi-drug resistance; Minimal inhibitory concentrations

Introduction
Tuberculosis (TB) currently remains a major health issue worldwide [1]. In 2014, 3.5% of new and 20.5% of previously treated TB cases was estimated to have Multidrug-resistant TB (MDR-TB), defined as resistance to at least isoniazid and rifampin, and 9.0% of patients with MDR-TB had extensively drug-resistant TB (XDR-TB) globally. XDR tuberculosis is defined as tuberculosis with resistance to at least isoniazid, rifampin, a fluoroquinolone, and 1 of 3 injectable second-line drugs (aminocillin, kanamycin, or capreomycin). While the alarming increase of MDR-TB and XDR-TB may hinder current advances in TB control, new anti-TB drugs or more effective therapeutic measures are urgently needed. Rifabutin (RFB) is the emergence of derivatives of rifampin (RFP) in recent years. RFB has strong antibacterial activity against Mycobacterium tuberculosis (MTB) and Mycobacterium non-tuberculosis (NTM), especially M. avium complex (MAC) [2]. Compared with rifampin, RFB causes fewer interactions with antiretroviral drugs, which is of relevance for HIV/TB coinfected [3,4]. With the advent of RFB, the effect of it on resistant Mycobacterium tuberculosis strains attracted the high attention of scholars. Related researches have been carried out. But study about the cross-resistance ratio between the two rifamycin derivatives is rare [5-9].

Our aim was to indicate the cross-resistance between rifampin (RFP) and rifabutin (RFB) in multi-drug resistant Mycobacterium tuberculosis (MDR-TB) clinical strains, and to provide the laboratory data for using RFB in the treatment of MDR-TB.

Materials and Methods
Test isolates
A total of ninety-nine clinical isolates of multidrug-resistant M. tuberculosis strains included in this study were selected from Shanghai Pulmonary Hospital, Tongji University School of Medicine. The isolates were obtained from sputum after culture with BACTEC MGIT 960 method and then were identified by biochemical tests. A strain of H37Rv (M. tuberculosis ATCC 27294), gift of the National Tuberculosis Reference Laboratory (Beijing, China) was used as control.

Antimicrobial agents
The antimicrobial agents RFB, RFP were purchased from Sigma Chemical Company (St Louis, MO) which were prepared in the manufacturer-recommended solvent to a stock solution concentration of 10,000 µg/ml according to manufacturers’ instructions and stored at -80°C until use.

Liquid culture medium
Liquid culture medium was Middlebrook 7H9 liquid culture containing 10% OADC enrichment ([Becton Dickinson Co., USA], the mixture of antimicrobial agents and growth indicator). Middlebrook 7H9 liquid culture was prepared according to the literature [10,11].

Inoculation preparation
M. tuberculosis suspension in log-phase growth was adjusted to 1 mg/mL. When aliquot of 100 µl M. tuberculosis suspension was added to 10 ml liquid culture medium, the final concentration was 10-3 mg/ml.

Antimycobacterial susceptibility testing
Minimum inhibitory concentration (MIC) of RFB and RFP as single agent was examined using the microwell plate method. Before use, aliquot of 100 µl liquid culture medium contained RFB or RFP dilutions was prepared and added to the sterile 96-well polystyrene U-bottom microdilution tray. The concentration range of RFB or RFP was from 0.5 µg/ml to 64 µg/ml. 100 µl suspension of M. tuberculosis was inoculated. The final concentration range of RFB or RFP was from 0.25 µg/ml to 32 µg/ml. Two drug-free controls were inoculated with

*Corresponding author: Heping Xiao, Department of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Rd., Shanghai 200433, People’s Republic of China, Tel: 86-21-65115006; Fax: 86-21-65112986; E-mail: xiaoheeping_sans@163.com

Received July 21, 2015; Accepted August 17, 2015; Published August 21, 2015

Citation: Yan L, Gao L, Cui Z, Hu Z, Lu J, et al. (2015) Investigation of Cross-Resistance between Rifampin and Rifabutin in Multi-Drug Resistant Mycobacterium tuberculosis. Med Chem 5: 412-414. doi:10.4172/2161-0444.1000293

Copyright: © 2015 Yan L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The same suspensions diluted 1:1, 1:10 respectively; the negative control was sat at the same time. After inoculation, the culture media was incubated at 37°C. The results were observed daily after seven days to fourteen days. The appearance of visible white bacterial precipitation in the bottom of the well indicates positive. The MIC of RFB or RFP is the lowest concentration inhibiting the visible growth of the bacteria. The critical test concentration for RFB-resistant strains was 0.5 µg/ml and for RFP was 1 µg/ml according to previous reports [12,13].

**Statistical analysis**

Statistical analyses were conducted using SPSS statistical software (SPSS Statistics 17.0; SPSS, Inc., Chicago, IL, USA). Comparisons of positive rates between different groups were analyzed using Pearson's χ² test.

**Results**

The RFB MIC distribution for the tested 99 MDR-TB clinical isolates was from <0.25 to 16 µg/ml (median 2 µg/ml) and the RFP MIC distribution was from 2 to >32 µg/ml (median 12 µg/ml), respectively. The difference showed statistically significant (χ²=125.905, p<0.001). The MIC of RFB was 1/8-1/32 of RFP, which are detailed in Table 1. The distribution curve of MIC of RFB and RFP was shown in Figure 1. Of the 99 clinical isolates tested, 14 of which were susceptible to RFB, 85 were resistant to RFB. The cross-resistant ratio between RFP and RFB was 85.86% and increased with the resistant level of RFP. For strains with a RFP MIC of 2 – 4 µg/ml, all were susceptible to RFB. For strains with a RFP MIC of 8 – 16 µg/ml, 44.44% were susceptible to RFB. For strains with a RFP MIC of ≥ 32 µg/ml, only 1(1.82%) was susceptible to RFB.

**Discussion**

There are some studies on cross-resistance to RFB and RFP. They showed different results [5-9]. It ranged from 54% to 88% [5-7]. But for the study of MDR-TB, we only found two articles with the results of 87% and 73%, respectively [8,9]. The cross-resistance ratio in this study was 85.86%. The difference may be due to the different research methods. We used liquid culture medium in this study to avoid drug explanation [14]. In the study of Senol and Sarıbas, test was conducted using the proportion method on L-J medium to RFB mono-resistant isolates and some MDR-TB.

We also found that the cross-resistance ratio between RFB and RFP rose with the degree increase of RFB resistance, which is consistent with other research [15]. About half of the moderate RFP-resistant MTB and almost all of the low RFP-resistant MTB were still susceptible to RFB. Previous studies have shown that certain mutations in the rpoB RRDR are more likely to confer higher levels of RFP resistance. At the same time, certain rpoB mutations are more likely to confer lower levels of RFP resistance. Jamieson et al. reported that high MICs for RFP and RFB are associated with specific mutations at codons 531 and 526, while mutations at other positions are generally associated with low or moderate MICs. But it’s a pity that we have not done related research for many reasons [16].

An important finding of this research is that the RFB MIC of the 99 MDR-TB isolates tested was much lower than RFP MIC (1/8-1/32). This is likely because RFB have higher affinity with the β-subunit of the bacterial RNA polymerase encoded by the rpoB gene [17]. We speculated that in clinical practice MDR-TB patients may be treatable with RFB. Unfortunately, there are very limited published data supporting the successful treatment of MDR-TB with RFB [18-21].

| Subgroup          | Isolates | RFB-MIC (µg/ml) | RFP-MIC (µg/ml) |
|-------------------|----------|-----------------|-----------------|
| RFB-MIC2 ug/ml    | 4        | 0.25            | 0               |
| RFB-MIC4 ug/ml    | 5        | 0.5             | 0               |
| RFB-MIC8 ug/ml    | 3        | 1               | 0               |
| RFB-MIC16 ug/ml   | 6        | 2               | 0               |
| RFB-MIC32 ug/ml   | 26       | 0               | 18              |
| RFB-MIC>32 ug/ml  | 55       | 1               | 13              |

Table 1: RFB MIC and RFP MIC for MDR-TB.
However, the synergistic effect is crucial for assessing the effectiveness of the anti-tuberculosis chemotherapy. In our another study of *in vitro* synergism of RFB with Moxifloxacin(Mfx) and Pasiniazid(PA) on ten MDR-TB and ten XDR-TB by a three-dimensional checkerboard in Middlebrook 7H9 broth microdilutions, RFB did not show strong synergistic effect with Mfx and PA (F=0.003) [22]. What exactly is now required to be investigated is the synergistic effect of RFB with other anti-tuberculosis drugs.

We conclude that about half of the moderate RFP-resistant MTB and almost all of the low RFP-resistant MTB were still susceptible to RFB. When MTB was moderately resistant to RFP (MIC 8-16 µg/ml), RFB was recommended only in the case of deficiency of sensitive drug to compose DR-TB chemotherapy scheme. When MTB was highly resistant to RFP (MIC ≥ 32 µg/ml), RFB was not recommended clinically.

**Acknowledgements**

Liping Yan and Li Gao contributed equally to this manuscript. This study was funded by the National Key Project for Infectious Disease (No. 2013ZX10003009).

**References**

1. WHO (2014) Global tuberculosis control-epidemiology, strategy, financing. Geneva, World Health Organization.
2. Wehrl W, Nuesch J, Knusel F, Staelinh M (1966) Action of rifamycins on RNA polymerase. Biochim Biophys Acta 157: 215-217.
3. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Elkind SC, et al. (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167: 603-662.
4. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, et al. (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 16: 75-83.
5. Saribas Z, Kocagoz T, Alp A, Gunalp A (2003) Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates by heteroduplex analysis and determination of rifamycin cross-resistance in rifampin-resistant isolates. Clin. Microbiol 41: 816-818.
6. Uzun M, Erturan Z, Ang O (2002) Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis 6: 164-165.
7. Senol G, Erbaycu A, Oztas A (2005) Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey. J Chemother 17: 380-384.
8. Chien HP, Yu MC, Ong TF, Lin TP, Luh KT (2000) In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan. J Formos Med Assoc 99: 408-411.
9. Chikamatsu K, Mizuno K, Yamada H, Mittara S (2009) Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains. Kekkaku 84: 631-633.
10. Rey-Jurado E, Tudo G, de la Bellacasa JP, Espasa M, Gonzalez-Martin J (2013) In vitro effect of three-drug combinations of antituberculosis agents against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 41: 278-280.
11. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, et al. (2009) Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 180: 273-280.
12. Kruuner A, Yates MD, Drobniewski FA (2006) Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of firstand second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. Clin Microbiol 44: 811-818.
13. Rusch-Gerdes, Pflffer GE, Casal M, Chadwick M, Siddiqi S (2006) Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. Clin Microbiol 44: 688-692.
14. Heifets L (1988) Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am Rev Respir Dis 137: 1217-1222.
15. Yang B, Koga H, Ohno H, Ogawa K, Fukuda M, et al. (1998) Relationship between antimycobacterial activities of rifampin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. Antimicrob Chemother 42: 621-628.
16. Jamieson FB, Guthrie JL, Neemuchwala A, Lastovetska O, Melano RG, et al. (2014) Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol 52: 2157-2162.
17. Bodmer T, Bernasconi C, Zuercher G (1993) Molecular basis of rifabutine susceptibility in rifampin resistant Mycobacterium tuberculosis (abstract no 1583). In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology.
18. [No authors listed] (1992) A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council. Tuber Lung Dis 73: 59-67.
19. Gillespie SH, Baskerville AJ, Davidson RN, Felmingham D, Brysonc ADM, et al. (1990) The serum rifabutin concentrations in a patient successfully treated for multi-resistant Mycobacterium tuberculosis infection. J Antimicrob Chemoter 25: 490-491.
20. Pretet S, Lebeaut A, Parrot R, Truffot C, Grosset J, et al. (1992) Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M (Group for the Study and Treatment of Resistant Mycobacterial Infection). Eur Respir J 5: 680-684.
21. Jo KW, Ji W, Hong Y, Lee SD, Kim WS, et al. (2013) The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis. Respir Med 107: 292-297.
22. Liping Yan, Linlin Zhang, Hua Yang and Heping Xiao (2014) In Vitro Synergism Testing of Three Antimicrobial Agents against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis by Checkerboard Method. J Mol Pharm Org Process Res 3: 1.